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Background: In an effort to reduce necessary acquisition time to perform molecular breast imaging (MBI), we
compared diagnostic performance of MBI performed with standard 10-min-per-view acquisitions and half-time
5-min-per-view acquisitions, with and without wide beam reconstruction (WBR) processing.
Methods: Eighty-two bilateral, two-view MBI studies were reviewed. Studies were performed with 300 MBq Tc-99 m
sestamibi and a direct conversion molecular breast imaging (DC-MBI) system. Acquisitions were 10 min-per-view; the
first half of each was extracted to create 5-min-per-view datasets, and WBR processing was applied.
The 10-min-, 5-min-, and 5-min-per-view WBR studies were independently interpreted in a randomized, blinded fashion
by two radiologists. Assessments of 1 to 5 were assigned; 4 and 5 were considered test positive. Background parenchymal
uptake, lesion type, distribution of non-mass lesions, lesion intensity, and image quality were described.
Results: Considering detection of all malignant and benign lesions, 5 min-per-view MBI had lower sensitivity (mean of
70% vs. 85% (p≤ 0.04) for two readers) and lower area under curve (AUC) (mean of 92.7 vs. 99.6, p≤ 0.01) but had
similar specificity (p = 1.0). WBR processing did not alter sensitivity, specificity, or AUC obtained at 5 min-per-view.
Overall agreement in final assessment between 5-min-per-view and 10-min-per-view acquisition types was near perfect
(κ = 0.82 to 0.89); however, fair to moderate agreement was observed for assessment category 3 (probably benign)
(κ = 0.24 to 0.48). Of 33 malignant lesions, 6 (18%) were changed from assessment of 4 or 5 with 10-min-per-view MBI
to assessment of 3 with 5-min-per-view MBI. Image quality of 5-min-per-view studies was reduced compared to
10-min-per-view studies for both readers (3.24 vs. 3.98, p < 0.0001 and 3.60 vs. 3.91, p < 0.0001). WBR processing
improved image quality for one reader (3.85 vs. 3.24, p < 0.0001).
Conclusions: Although similar radiologic interpretations were obtained with 10-min- and 5-min-per-view DC-MBI,
resulting in substantial agreement in final assessment, notable exceptions were found: (1) perceived image quality at
5 min-per-view was lower than that for 10-min-per-view studies and (2) in a number of cases, assessment was
downgraded from a recommendation of biopsy to that of short interval follow-up.
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Recent advancements in dedicated gamma camera tech-
nology to permit imaging at low radiation doses now allow
consideration of their use in breast cancer screening. In
contrast to breast-specific gamma imaging (BSGI), which
uses a single detector comprising a pixelated array of
scintillating crystals [1], a new generation of systems now* Correspondence: mbi@mayo.edu
1Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN
55905, USA
Full list of author information is available at the end of the article
© 2014 Hruska et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pemploy a dual-head configuration of solid-state (non-scin-
tillating) detectors [2]. These direct conversion molecular
breast imaging (DC-MBI) systems directly convert gamma
ray energy to electronic signal, offering improved count
sensitivity and energy resolution compared to older gener-
ation scintillating systems.
The addition of MBI, performed with 740 MBq (20 mCi)
Tc-99 m sestamibi and a cadmium zinc telluride (CZT)
DC-MBI system, to screening mammography in women
with dense breasts was previously reported. Compared ton Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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alone, addition of prevalent MBI significantly increased
cancer detection rate from 3.2 to 10.7 cancers detected
per 1,000 women screened [3]. Importantly, addition of
MBI to mammography did not reduce positive predictive
value (PPV) compared to that from mammography alone,
whereas studies examining addition of whole-breast screen-
ing ultrasound to screening mammography in women with
dense breasts have shown reduction in PPV [4,5].
Following the implementation of a registered high-
sensitivity collimation specifically designed for dual-head
DC-MBI systems [6] and a CZT-specific energy acceptance
window to capture additional photopeak counts [7], DC-
MBI is now routinely performed at our institution with
injection of approximately 220 to 300 MBq (6 to 8 mCi)
Tc-99 m sestamibi, which corresponds to an effective
(whole-body) radiation dose of 1.8 to 2.4 mSv. A similar
cancer detection rate of 12.0 per 1,000 has been obtained
with addition of this low-dose MBI to screening mam-
mography in women with dense breasts [8]. While MBI’s
current effective dose of 1.8 to 2.4 mSv is higher than that
from the two-view digital mammography (approximately
0.5 mSv) or two-view digital mammography combined
with tomosynthesis (approximately 1.0 to 1.5 mSv) [9], all
of these effective doses are at or below annual natural
background radiation levels (worldwide average 2.4 mSv,
range 1 to 13 mSv) [10]. At these low radiation levels,
an assessment of risk has been determined unwarranted,
according to recent statements issued by United Nations
Scientific Committee on the Effects of Atomic Radiation
(UNSCEAR) and American Association of Physicists in
Medicine [11,12]. Nevertheless, in an effort to keep doses
from medical imaging as low as reasonably achievable
and to promote acceptance of MBI in the screening envir-
onment, further dose reductions may be desirable.
Recent work showed feasibility of performing MBI with
either a further reduced dose of 150 MBq Tc-99 m sesta-
mibi or, alternatively, using a reduced acquisition length of
5minperview while keeping administered dose at 300 MBq
[7,13]. With the current 10-min-per-view protocol, a
two-view bilateral MBI requires at least 40 min of imaging
time. Reduction in the acquisition length of MBI is de-
sirable in order to allow greater throughput, more easily
permit the collection of additional views within a single
exam time when necessary, and likely make the exam more
comfortable for some patients who have difficulty remaining
still throughout each 10-min acquisition.
Similar efforts to reduce dose and/or acquisition length
for cardiac single photon emission tomography (SPECT)
led to the development of a reconstruction technique called
wide beam reconstruction (WBR) [14,15]. WBR incorpo-
rates the exact collimator geometry, patient-to-detector
distance, and statistical characteristics of photon counts to
provide both resolution recovery and noise reduction [16].A modified WBR algorithm has been specifically created
for DC-MBI systems.
Our objective was to compare diagnostic performance
of three MBI acquisition durations: (a) 10 min-per-view,
(b) 5 min-per-view, and (c) 5 min-per-view with WBR
processing.
Methods
Molecular breast imaging studies
MBI studies were collected under IRB-approved, HIPAA-
compliant research protocols and written informed consent
was obtained from all participants.
MBI was performed on a DC-MBI system comprising
two compact CZT detectors with 1.6 mm × 1.6 mm
pixels (LumaGem, Gamma Medica, Salem, NH, USA)
and equipped with high sensitivity registered collimators,
as previously described [6]. An energy acceptance window
of 110 to 154 keV was used [7].
A dispensed dose of 300 MBq (8 mCi) Tc-99 m sestamibi
was administered to each patient by intravenous injection.
As Tc-99 m sestamibi is known to adhere to plastic walls
of syringes, residual dose in the syringe was measured after
injection. Approximately 20% residual activity remained in
the syringe, on average, giving an average administered
dose of 240 MBq (6.5 mCi) [17]. Imaging commenced
within 2 to 5 min of injection.
Two images of each breast were acquired with the
camera orientation analogous to craniocaudal and medio-
lateral oblique mammographic views. Acquisitions were a
total of 10 min per view, and each was acquired in four
2.5-min frames; the first two frames of each acquisition
were summed to create a 5-min-per-view dataset for each
patient. A first iteration of the DC-MBI WBR algorithm
(UltraSPECT, Haifa, Israel), which incorporated collimator-
specific information from both detector views in recon-
struction, was applied to 5-min-per-view datasets.
Image count density was measured with a region of
interest including all breast tissues, excluding lesions, in
craniocaudal views of the left breast of each patient and
expressed in counts/cm2.
Reader study case selection
Sample size was selected for determining overall proportion
of agreement in disease classification (test positive vs. test
negative) between 10-min- and 5-min-per-view MBI. For
5-min-per-view MBI to be considered a viable alternative
to 10-min-per-view MBI, agreement in disease classification
between the two acquisition types was expected to be 0.90.
A non-inferiority margin of 0.10 was proposed as the
largest difference from 0.90 that could be observed in
order to consider the observed agreement non-inferior to
the 0.90 assumption. Assuming α level = 0.05, 82 patients
with paired 5-min-per-view and 10-min-per-view studies
yield 80% statistical power to reject the null hypothesis of
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disease-positive and 60% disease-negative cases (including
those with benign lesions) in order to have approximately
half of the breasts be positive for a lesion and half negative.
This constraint was required to avoid attenuation of the
kappa statistic (see statistical methods below). For testing
overall diagnostic accuracy, quantified as area under curve
(AUC) of the receiver operating characteristic (ROC) curve,
this sample size and case mix yielded 90% power to detect
at least a 0.2 increase in AUC (from null value of 0.5 to
0.7) at the α = 0.05 significance level.
MBI studies were retrospectively selected to reflect the
typical range of histopathologies, lesion sizes, lesion uptake
intensities, and image count densities observed in clinical
practice. Studies with distinguishing features that could be
easily recalled, such as very large lesions, breast implants,
or artifacts, were not selected. Patients with pathology
findings of ductal carcinoma in situ or invasive cancer were
considered to have positive reference standard. Patients
with any other pathology findings or benign imaging find-
ings at >12 months in those not biopsied were considered
to have negative reference standard.
MBI interpretation
Two breast imaging fellowship-trained radiologists with 2
and 3 years of experience interpreting MBI each performed
three independent reading sessions, separated by 4 to 6
weeks, of 82 MBI studies at each session. Each session
comprised a random order of studies from all three ac-
quisition types (10 min-per-view, 5 min-per-view, or
5 min-per-view with WBR); only one of the three acquisi-
tion types appeared for each patient per session. Readers
were blinded to acquisition type, other imaging findings,
and clinical information.
MBI studies were interpreted according to a validated
lexicon for gamma imaging of the breast [18,19]. Back-
ground uptake in normal breast parenchyma was described
as photopenic, minimal mild, moderate, or marked. Any
identified lesions were categorized as mass or non-mass
uptake; non-mass uptake distribution was further described
as either focal area, segmental, regional, multiple regions,
or diffuse. Lesion intensity was qualitatively described as
photopenic, mild, moderate, or marked.
Readers assigned a final assessment on a per-breast
basis using a 1 to5 scale that parallels BI-RADS assessment
categories. Assessments and associated recommendations
are as follows: 1 (negative) or 2 (benign, return to routine
screening), 3 (probably benign, short-interval follow-up),
and 4 (suspicious) or 5 (highly suggestive of malignancy,
biopsy) [20]. An overall assessment of diagnostic image
quality was assigned, with consideration given to the noise
level in the images. Image quality was scored on a 1 to 5
scale as follows: 1 (poor, non-diagnostic); 2 (suboptimal,
worse than routine), 3 (acceptable, noisier than routine), 4(good, same as routine), and 5 (excellent, better than
routine).
Data analysis
Statistical analysis system (SAS) software (SAS Institute,
Inc., Cary, NC, USA), version 9.3, was used for all analyses.
Using recommendation of biopsy as the threshold,
each breast was classified using a 1 to 5 rating scale. Assess-
ments of 1, 2, and 3 were considered test negative; 4 and 5
were considered test positive. Because lesion detection was
the objective of the analysis, sensitivity was calculated two
ways: first, considering the sensitivity for detection of all
lesions (including malignant and benign) and second,
considering sensitivity for detection of cancers only. Sensi-
tivity, specificity, AUC, and average image quality score
for each acquisition type were calculated on the per-breast
level under the statistical assumption that the individual
breast readings were statistically independent. McNemar’s
test for correlated proportions was used to compare sensi-
tivities and specificities; Chi-square analysis was used to
compare AUCs; and Wilcoxon signed-rank test was used
to compare image quality scores between acquisition types.
Sensitivities of subgroups within each acquisition type were
compared with Fisher’s exact probability test. Two-sided
p values were reported, and p < 0.05 was considered sta-
tistically significant.
Proportion of agreement between each individual reader’s
interpretation of 10-min-per-view MBI with that of the
5-min-per-view MBI, with and without WBR, was deter-
mined for each descriptor. Weighted kappa (κ) statistic,
which is the proportion of agreement expected beyond
chance, was reported on the per-breast level. The scale
established by Landis and Koch was followed: κ between 0
and 0.2 indicates slight agreement, 0.21 to 0.4 indicates
fair agreement, 0.41 to 0.6 indicates moderate agreement,
0.61 to 0.8 indicates substantial agreement, and κ above
0.81 indicates near-perfect agreement [21].
Additional lesions described beyond those identified at
case selection were not included in agreement analysis.
Final assessment categories were combined into three
groups for agreement analysis: 1 and 2, 3,and 4 and 5.
For determining overall proportion of agreement in dis-
ease classification, assessments of 1 to 3 and 4 to 5 were
grouped.
Results
Characteristics of selected cases
Average age of patients was 61 years (s.d. 11.2 years;
range 41 to 83 years). In the 82 patients, reference stand-
ard was positive for breast cancer in 33 and negative in 49.
A total of 49 lesions in 48 patients were identified at case
selection, including 33 malignant and 16 benign lesions.
There were 115 negative breasts for specificity analysis
(Figure 1). One patient had a single benign lesion identified
Figure 1 Number of subjects, breasts, and lesions included for sensitivity and specificity analysis.
Table 1 Characteristics of 49 lesions in 48 patients from a
total of 82 MBI studies
Lesion histopathology Number of lesions
(% of 49 total lesions)
Malignant lesions 33 (67)
Invasive ductal carcinoma 23 (47)
Invasive lobular carcinoma 3 (6)
Mixed invasive ductal/lobular 1 (2)
Ductal carcinoma in situ 4 (8)
Mucinous carcinoma 1 (2)
Tubular carcinoma 1 (2)
Benign lesions 16 (33)
Atypia or LCIS 2 (4)








Lesion size and intensity category
≤ 10 mm and mild intensity 13 (27)
≤ 10 mm and moderate intensity 4 (8)
≤ 10 mm and marked intensity 0
> 10 mm and mild intensity 5 (10)
> 10 mm and moderate intensity 17 (35)
> 10 mm and marked intensity 10 (20)
Numbers in parentheses are percentages and percentages are rounded. All patients
had a single lesion diagnosed, except for one patient who had a single
benign lesion in each breast. Lesion size was the greatest dimension of lesion
measured on MBI. Both lesion size and lesion intensity listed were based on a
clinically-interpreted MBI report of 10-min-per-view acquisition and used to
guide appropriate selection for the reader study.
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Table 1.
Median size of all 49 lesions was 1.3 cm (s.d. 0.7 cm;
range 0.4 to 3.1 cm) and median size of the 33 malignancies
was 1.4 cm (s.d. 0.7 cm; range 0.5 to 3.1 cm). Of 33 malig-
nant lesions, 28 were invasive; of these 29 invasive cancers,
22 were node negative, 5 had positive micrometastasis
(N1mi), 1 had a single positive node (N1), and 1 had
metastatic breast cancer.
Median image count density of 10-min-per-view MBI
studies was 1,574 counts/cm2, with a range of 527 to
2,930 counts/cm2. In 10-min-per-view studies, 17 of 82
(21%) were considered low count density (<1,150 counts/
cm2), 38 of 82 (46%) were considered intermediate count
density (1,150 to 1,750 counts/cm2), and 27 of 82 (33%)
were considered high count density (>1,750 counts/cm2).
Corresponding 5-min-per-view datasets for each patient
contained approximately half the count density of the
10-min-per-view acquisitions.
Diagnostic accuracy
Sensitivity and specificity obtained for each acquisition
type is shown in Figure 1. Table 2 expands upon these
results for all lesions and malignant lesions only, respect-
ively, by lesion characteristics. Considering detection of all
49 malignant and benign lesions, sensitivity was signifi-
cantly lower for 5-min-per-view studies compared to
10-min-per-view for both readers; specificity was nearly
unchanged. Considering detection of the 33 malignant
lesions only, sensitivity was numerically lower and specifi-
city was numerically higher for 5-min-per-view MBI com-
pared to 10-min-per-view MBI; however, differences were
not statistically significant. Application of WBR processing
Table 2 Diagnostic performance of each type of MBI acquisition








































































































































p value≤ 10 mm
vs. > 10 mm**
0.70 0.20 0.01 0.02 0.01 0.01
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moderate/high
intensity**

















































































































































































































p value≤ 10 mm
vs. > 10 mm**
0.24 0.32 0.14 0.053 0.036 0.080
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moderate/high
intensity**














































































































Diagnostic performance of each type of MBI acquisition interpreted independently by two readers, first considering detection of both malignant and benign lesions and second considering detection of only malignant
lesions. Numbers in parentheses are percentages, and percentages are rounded.MBI, molecular breast imaging; WBR, wide beam reconstruction; NDP, unable analyze due to lack discordant pairs. A per-breast final assessment
of 1, 2, or 3 was considered test negative, and final assessment of 4 or 5 was considered test positive. Lesion size and intensity classification were determined at case selection based on the clinically interpreted MBI report of
the 10-min-per-view acquisitions. Image count density was measured in the background (non-lesion) region of benign breast tissue on the 10-min-per-view MBI acquisition. Count density was defined as low (<1,150 counts/
cm2), intermediate (1,150 to 1,750 counts/cm2), or high (>1,750 counts/cm2). *p values for sensitivity and specificity were calculated using McNemar’s test for correlated proportions, p values for ROC results were calculated
using Chi-square analysis, and p values for image quality scores were calculated using Wilcoxon signed-rank test. **p values were calculated using Fisher’s exact probability test. ***Results for sensitivity for all lesions are given
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or specificity.
Sensitivity for lesion detection was impacted by lesion
size and intensity (Table 2). Sensitivity for lesions ≤10 mm
was consistently lower than that for cancers larger than
10 mm for all acquisition types and significantly lower for
reader 2. Sensitivity for mild-intensity lesions was signifi-
cantly lower than that for moderate or marked intensity
lesions for all acquisition types for both readers. No
significant difference in sensitivity was observed between
studies with starting low image count density at 10 min-
per-view compared to studies with starting intermediate or
high image count density for any acquisition type. How-
ever, the effect of image count density on lesion detection
is reflected in the decreased sensitivity for lesion detection
with proportional halving of the count density as image
acquisition duration was halved from 10 to 5 min-per-view.
When considering detection of all lesions, ROC analysis
demonstrated a high AUC of above 91 for all acquisition
types (Table 2); however, AUC was significantly lower at
5 min-per-view compared to 10 min-per-view for both
readers. The application of WBR processing did not signifi-
cantly alter the AUC obtained with 5-min-per-view MBI.
Example images of the three acquisition types in patients
are shown in Figures 2 and 3.
Changes in final assessment score
In 15 patients, a lesion that was detected (assessment 4
or 5) on 10-min-per-view MBI by either reader was given
a test negative assessment of 1 to 3 on the 5 min-per-view
or 5-min-per-view WBR study by either one or both
readers (Table 3). The 15 lesions included 6 malignancies
and 9 benign lesions. All were mild intensity except for
one of the invasive ductal carcinomas which was moderate
intensity; size ranged from 0.5 to 2.5 cm.Figure 2 MBI study performed with injection of 290 MBq Tc-99 m ses
a 0.8-cm ductal carcinoma in situ appears as a moderate intensity mass (arr
view, (B)5 min-per-view, and (C) 5 min-per-view with WBR. Image count de
considered low. Both readers assigned a test positive assessment of 4 (suspOf all 15 lesions with downgraded assessments at
5 min-per-view, 12 of 15 (80%) were categorized as mild
intensity lesions and the other 3 of 15 (20%) were moder-
ate intensity. Approximately half (7 of 15 (47%)) of these
lesions were ≤10 mm. Only 1 of 15 (7%) was in a patient
with a low image count density. Eleven of the 15 (73%)
test-negative lesions on 5 min-per-view or 5-min-per-view
WBR acquisitions received a final assessment of 3 (prob-
ably benign) by either one or both readers, indicating
that the lesion was observed but not given a test positive
assessment of 4 or 5 that would lead to recommendation
of biopsy.
For reader 1, the application of WBR to the 5-min-
per-view acquisitions resulted in an upgrade from a test
negative to test positive assessment in only one lesion,
a malignant lesion in patient no. 3, and a downgraded
assessment from test positive to test negative in 2 benign
lesions (patient nos. 7 and 13). For reader 2, application of
WBR resulted in an upgrade from test negative to test
positive in four lesions: one malignancy in patient no.
2 and three benign lesions in patient nos. 13 to 15;
however, two malignant lesions (patient nos.5 and 6) and
one benign lesion (patient no. 9) were downgraded from
test positive to test negative.
Image quality
For both readers, average image quality scores were sig-
nificantly lower for 5-min-per-view acquisitions compared
to 10-min-per-view acquisitions (3.24 vs. 3.98, p < 0.0001
and 3.60 vs. 3.91, p < 0.0001) as shown in Table 4. For
reader 1, application of WBR led to improvements in
5-min-per-view image quality (3.85 vs. 3.24, p < 0.0001),
resulting in a score similar to 10-min-per-view studies.
However, reader 2 results did not show improvement in
image quality with WBR.tamibi and a dual-head DC-MBI system. In this 63-year-old woman,
ow) and was detected at all three acquisition types: (A) 10 min-per-
nsity of 1,020 counts/cm2 in the 10-min-per-view acquisition was
icious) for all three acquisition types.
Figure 3 MBI study performed with injection of 320 MBq Tc-99 m sestamibi and a dual-head DC-MBI system. In this 45-year-old woman,
a 0.5-cm invasive ductal carcinoma appears as a mild intensity, focal area of non-mass uptake (arrow). Image count density of 1,800 counts/cm2
in the 10-min-per-view acquisition was considered high. The cancer was detected at (A) 10-min-per-view, but not at (B) 5 min-per-view or (C)
5 min-per-view with WBR. At 10 min-per-view, one reader assigned a test positive assessment of 4 (suspicious), and the other reader gave a test
negative assessment of 3 (probably benign). For both 5 min-per-view and 5-min-per-view WBR acquisitions, both readers assigned test negative
assessments of 2 (benign). These images correspond with patient no. 4 in Table 3.
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quality score of 1. Of the 82 studies performed at 10 min-
per-view, only one received an image quality score of 2
from one reader; image count density in that study was
739 counts/cm2. In the corresponding 82 studies at
5 min-per-view, a total of 12 patients were assigned
with image quality scores of 2 by the combination of
results from both readers; average image count density
in those studies was 612 counts/cm2, ranging from 264
to 1,009 counts/cm2.Interpretation agreement
Agreement of 10-min-per-view interpretations with 5-
min-per-view interpretations is given in Table 5. Overall
proportion of agreement in disease classification between
10 min- and 5-min-per-view MBI, determined by grouping
test negative (1 to 3) and test positive (4 to 5) assessments,
was 154 of 164 (94%) for reader 1 and 156 of 164 (95%)
for reader 2.
Overall kappa statistic calculations indicated substantial
to near-perfect agreement of 5-min-per-view studies
(with and without WBR) and 10-min-per-view studies
in describing background parenchymal uptake (κ = 0.79 to
0.89), lesion type (κ = 0.67 to 0.78), lesion intensity (κ = 0.80
to 0.85), and final assessment (κ = 0.82 to 0.89). Moderate
to substantial overall agreement was observed in describing
the distribution of non-mass lesions (κ = 0.46 to 0.70).
For the final assessment descriptor, substantial to near-
perfect agreement was observed for the grouped assessmentcategories of 1/2 and 4/5, but only fair to moderate
agreement was observed for the middle assessment cat-
egory of 3.
Description of image quality showed the lowest agree-
ment; slight to fair overall agreement (κ = 0.04 to 0.21)
was observed for both readers.Discussion
MBI performed at 5 min-per-view demonstrated decreased
sensitivity for lesion detection, similar specificity, and
decreased AUC compared to standard 10-min-per-view
MBI. According to criteria for non-inferiority established
a priori, where ‘non-inferior’ was defined as no more than
10% reduction in the expected 90% agreement in disease
classification (test negative vs. test positive), 5-min-per-view
MBI performance is consistent with the definition of being
non-inferior to 10-min-per-view MBI as 94% to 95% overall
agreement between the two acquisition types was observed.
However, due to the significantly lowered sensitivity,
coupled with lower perceived image quality scores and a
substantial number of downgraded assessments at 5 min-
per-view, the standard 10-min-per-view acquisitions for
DC-MBI are preferred.
In general, a high level of agreement was observed
between interpretations of 10-min- and 5-min-per-view
acquisitions. However, the fair to moderate agreement ob-
served for assessment category 3 is of clinical importance.
Similar to other retrospective reader study designs, only
assessments with recommendation of biopsy (4 or 5) were



























0.9 III N0 Mild High 3 3 1 3
2 Invasive
ductal carcinoma
1.8 II N0 Moderate Intermediate 3 3 3 (4)
3 Invasive
ductal carcinoma
2.5 I N1mi Mild Intermediate 3 (4) (4) (4)
4 Invasive
ductal carcinoma
0.5 III N1 Mild High 2 2 2 2
5 Invasive
ductal carcinoma
2.0 II N0 Mild Intermediate 3 3 (4) 3
6 Mucinous
carcinoma
1.1 I N0 Mild Intermediate 3 3 (4) 3
7 Atypical ductal
hyperplasia
0.9 - - Mild Intermediate (4) 3 3 3
8 Benign
fibrocystic changes
0.4 - - Mild Intermediate 1 1 1 1
9 Benign
fibrocystic changes
1.8 - - Moderate High 3 3 (4) 3
10 Fibroadenoma 0.8 - - Mild High 2 1 1 2
11 Fibroadenoma 1.0 - - Mild Intermediate 1 3 3 3
12 Benign breast
parenchyma
3.0 - - Mild High 1 1 1 3
13 Benign
lymph node
0.8 - - Mild Low (4) 3 3 (4)
14 Benign breast
parenchyma
1.1 - - Mild High 1 3 3 (4)
15 Benign
lymph node
1.5 - - Moderate Intermediate 3 3 3 (4)
No. of patients with assessment 3 7 10 6 7
No. of patients with assessment 1 or 2 6 4 5 3
Assessments of 4 or 5 were considered test positive; assessments of ≤3 were considered test negative. aFinal assessment is given for lesions detected by either
reader on 10-min-per-view acquisitions but not detected by at least one reader on 5 min-per-view or 5-min-per-view WBR acquisitions. Assessments in parentheses
indicate a detected lesion. Lesion size and intensity classification was determined at case selection based on the clinically-interpreted MBI report of the 10-min-per-view
acquisitions. Image count density was measured in the background (non-lesion) region of benign breast tissue on the 10-min-per-view MBI acquisition. Count density
was defined as low (<1,150 counts/cm2), intermediate (1,150 to1,750 counts/cm2), or high (>1,750 counts/cm2). Note: in one additional patient, a benign lesion was
considered undetected at 10 min-per-view (assessment = 3) but was detected at 5 min-per-view and 5 min-per-view with WBR (assessment of 4) by reader 1.
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grades from assessment 4 to 5 on 10-min-per-view MBI
to assessment 3 on 5-min-per-view MBI were observed in
6 of 33 (18%) patients with breast cancer and 9 of 16
(56%) patients with benign lesions. These downgradesTable 4 Image quality scores for each MBI acquisition type in
10 min-per-view 5 min-per-view 5 min-pe
Average S.D. Average S.D. Average
Reader 1 3.98 0.42 3.24 0.66 3.85
Reader 2 3.91 0.28 3.60 0.61 3.49would result in changing recommendation from biopsy to
short interval MBI follow-up at 6 months.
The six malignant cases that were test negative on 5-
min-per-view MBI all presented as focal areas of non-mass
uptake. Five were mild intensity and one was moderateterpreted independently by two readers








0.45 <0.0001 0.086 <0.0001
0.63 <0.0001 <0.0001 0.17
Table 5 Agreement between each reader’s interpretation of 5-min-per-view and 10-min-per-view MBI






























0.84 (0.76, 0.92) 157/164
(96)(91, 98)
0.89 (0.81, 0.98) 150/164
(91)(86, 95)
0.79 (0.69, 0.89) 150/164
(91)(86, 95)
0.82 (0.73, 0.91)
Photopenic 24 0.87 (0.75, 0.98) 0.87 (0.75, 0.98) 22 0.82 (0.68, 0.96) 0.77 (0.62, 0.92)
Mild 124 0.84 (0.75, 0.94) 0.92 (0.84, 0.99) 128 0.81 (0.70, 0.92) 0.79 (0.67, 0.90)
Moderate 8 0.47 (0.16, 0.78) 0.79 (0.59, 0.99) 8 0.58 (0.31, 0.84) 0.65 (0.39, 0.91)
Marked 8 0.74 (0.49, 0.98) 1.00 (1.00, 1.00) 6 0.49 (0.07, 0.92) 0.85 (0.65, 1.00)
Lesion type 138/164
(84)(78, 89)
0.67 (0.56, 0.78) 142/164
(87)(81, 91)
0.74 (0.63, 0.84) 147/164
(90)(84, 93)
0.76 (0.65, 0.87) 150/164
(91)(86, 95)
0.78 (0.68, 0.88)
No lesion 107 0.75 (0.64, 0.85) 0.83 (0.74, 0.92) 113 0.80 (0.70, 0.90) 0.81 (0.71, 0.91)
Mass 23 0.61 (0.42, 0.80) 0.69 (0.53, 0.86) 11 0.85 (0.68, 1.00) 0.81 (0.62, 0.99)





0.46 (0.32, 0.61) 139/164
(85)(78, 89)
0.52 (0.37, 0.66) 147/164
(90)(84, 93)
0.68 (0.54, 0.82) 149/164
(91)(85, 94)
0.70 (0.57, 0.84)
No non-mass lesion 130 0.56 (0.40, 0.72) 0.61 (0.45, 0.76) 124 0.72 (0.59, 0.84) 0.74 (0.64, 0.86)
Focal area 30 0.48 (0.31, 0.66) 0.52 (0.35, 0.69) 38 0.75 (0.62, 0.87) 0.74 (0.61, 0.86)
Segmental 2 −0.01 (−0.02,0.00) 0.66 (0.05, 1.00) 1 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
Regional 2 −0.02(−0.03,0.00) −0.01 (−0.03,0.00) 1 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
Multiple regions 0 N/A N/A 0 N/A N/A
Diffuse 0 N/A N/A 0 N/A N/A
Lesion intensity 139/164
(85)(78, 89)
0.81 (0.73, 0.89) 145/164
(88)(83, 93)
0.85 (0.77, 0.92) 143/164
(87)(81, 91)
0.80 (0.71, 0.88) 146/164
(89)(83, 93)
0.85 (0.78, 0.92)
No lesion 107 0.76 (0.65, 0.87) 0.83 (0.74, 0.92) 114 0.78 (0.68, 0.89) 0.87 (0.79, 0.95)
Photopenic 2 −0.01 (−0.02,0.00) 1.00 (1.00, 1.00) 0 N/A N/A
Mild 20 0.46 (0.24, 0.67) 0.58 (0.39, 0.78) 31 0.63 (0.47, 0.78) 0.68 (0.53, 0.83)
Moderate 22 0.73 (0.57, 0.89) 0.77 (0.62, 0.92) 10 0.68 (0.44, 0.92) 0.53 (0.28, 0.77)





0.81 (0.73, 0.89) 144/164
(88)(82, 92)
0.82 (0.75, 0.90) 146/164
(89)(83, 93)
0.84 (0.76, 0.91) 151/164
(92)(87, 95)
0.89 (0.82, 0.95)
Assessment 1 or 2 107 0.80 (0.70, 0.90) 0.82 (0.73, 0.91) 112 0.92 0.81 (0.72, 0.91) 0.87 (0.79, 0.95)
Assessment 3 17 0.38 (0.14, 0.62) 0.48 (0.27, 0.69) 9 0.91 0.24 (−0.02,0.50) 0.44 (0.17, 0.72)




















Table 5 Agreement between each reader’s interpretation of 5-min-per-view and 10-min-per-view MBI (Continued)
Disease classification 154/164
(94)(89, 97)
0.83 (0.72, 0.93) 154/164
(94)(89, 97)
0.82 (0.72, 0.93) 156/164
(95)(90, 98)










40 0.83 (0.72, 0.93) 0.82 (0.72, 0.93) 43 0.95 0.87 (0.78, 0.96) 0.90 (0.82, 0.98)
Image quality 55/164
(34)(27, 41)
0.04 (−0.03, 0.11) 126/164
(77)(70, 83)
0.12 (−0.01, 0.26) 116/164
(71)(63, 77)
0.21 (0.09, 0.32) 92/164
(56)(48, 63)
0.04 (−0.04, 0.13)
1 - Poor, non-diagnostic 0 N/A N/A 0 N/A N/A
2 - Suboptimal,
worse than routine
2 0.16 (−0.04,0.36) −0.02 (−0.03,0.01) 0 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
3 - Acceptable,
noisier than routine
11 −0.06 (−0.14,0.01) 0.13 (−0.08,0.33) 14 0.23 (0.08, 0.38) 0.03 (−0.08,0.14)
4 - Good, same
as routine
141 −0.03 (−0.12,0.05) 0.17 (−0.02,0.36) 150 0.24 (0.11, 0.37) 0.05 (−0.05,0.15)
5 - Excellent, better
than routine
10 0.00 (0.00, 0.00) −0.02 (−0.05,0.00) 0 N/A N/A
Data are for 82 patients with 164 breasts. Unless otherwise noted, numbers in parentheses are percentages, and percentages are rounded. Number of breasts is those with given feature according to the readers’
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http://www.ejnmmires.com/content/4/1/5intensity. Mild intensity non-mass lesions represent the
most subtle of MBI-detectable findings and are often
not visible on all views. On subsequent review of these
cases, four were seen on a single view on a single pro-
jection only (i.e., were visible on only one of four images
provided for that breast). Because focal area non-mass
lesions are on the edge of MBI detectability, it is not
surprising that they were most affected by a decrease in
count density by halving acquisition duration in this
study.
Lesion intensity was identified as an important factor
in determining lesion detection for a given acquisition type,
as mild intensity lesions were less likely to be detected.
Lesion size also impacted lesion detection, with signifi-
cantly lower sensitivity observed for lesions ≤10 mm for
one reader.
Reduction in acquisition length by half results in half
the count density and a corresponding increase in noise
fraction by a factor of √2. Of lesions that were test positive
on 10 min-per-view, but test negative at 5 min-per-view
(Table 3), only one was in a low count density study.
Moderate or marked background parenchymal uptake
on MBI can obscure breast lesions. A limitation of this
study was that most patients had either photopenic or
mild background uptake; only four patients (eight breasts)
were assigned moderate or marked background uptake.
All lesions downgraded at 5 min-per-view (Table 3) were
in patients with photopenic or mild background uptake.
Hence, the effect of moderate or marked background par-
enchymal uptake on lesion detection at 5 min-view could
not be assessed in this study.
An additional limitation was that the detection task
was a combined detection and characterization process.
Lesions, when identified, were done so using the BI-RADS-
like assessment scale at the breast level. A subtlety of this
analysis is that breasts characterized as 3 were treated as
screen failures (MBI negative as a test result with a binary
decision).
Application of the current DC-MBI WBR algorithm to
5-min-per-view studies did not significantly impact diag-
nostic accuracy. WBR processing did result in better per-
ceived image quality for one reader. The usefulness of
WBR may therefore depend on reader preference for image
appearance. While WBR reduces appearance of image
noise, it may also create the perception of loss in overall
image contrast. In practice, we anticipate offering WBR
images as an adjunct dataset to unprocessed studies.
Conclusions
Findings indicate that the standard 10-min-per-view acqui-
sition duration for DC-MBI performed with 300 MBq Tc-
99 m sestamibi is preferred to 5-min-per-view acquisitions,
as sensitivity for lesion detection is reduced with shorter
imaging time. Although reduction to 5 min-per-viewresulted in similar radiologic interpretations, clinically
important exceptions of lower perceived image quality
and downgraded assessments from a recommendation of
biopsy to that of short interval follow-up were observed.
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